allo-asc-dfu

Cell therapyexperimental

Clinical trial activity

2 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Nov 30, 2018 (NCT03754465)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04569409Phase 3Jul 14, 2020Anterogen Co., Ltd., Catholic University of Korea, Korea University, Seoul National University, University of Ulsan
NCT03754465Phase 2Nov 30, 2018Anterogen Co., Ltd., University of Southern California
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Anterogen Co., Ltd.For profit2222018
Catholic University of KoreaAcademic/Hospital1012020
Korea UniversityAcademic/Hospital1012020
Seoul National UniversityAcademic/Hospital1012020
University of Southern CaliforniaAcademic/Hospital1012018
University of UlsanAcademic/Hospital1012020
6 organizations
Page 1 / 1